Podcast

Podcast: This Week in Managed Care - New Breast Cancer Guidelines, and Other News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included new radiology guidelines for early-stage breast cancer; 4 continuing healthcare challenges for President Donald Trump; and Medicare coverage for Dexcom's continuous glucose monitor.

Listen below or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Related Videos
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
John Buse, MD, PhD
SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1
Cathy Eng, MD, FACP, FASCO
Elevating Cancer Care Through Personalized Treatment
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
How Do Infusion Pharmacies Support Financial Sustainability in Oncology?
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
A Pharmacist's Role in Selecting Effective, Affordable Breast Cancer Therapies
Screenshot of an interview with Shaun McKenzie, MD
Identifying Good Candidates for Histotripsy to Treat Liver Tumors
Dr Andrew S. Oseran
Further Research Into Medicare Advantage Upcoding, Documentation Accuracy Needed
o Richard Hughes IV, JD, MPH, Epstein Becker Green
Payer Responsibility for Preventive Services May Hinge on Braidwood Decision
Dr Andrew S. Oseran
Chronic Condition Prevalence Similar in Medicare Advantage, Traditional Medicare Beneficiaries
Dr Andrew S. Oseran
Unpacking Medicare Advantage Criticism With Dr Andrew S. Oseran
Related Content
AJMC
April 3rd 2025

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims

Poorva M. Nemlekar, MS Katia L. Hannah, PhD, MPH Courtney R. Green, PhD Thomas Grace, MD Peter M. Lynch, MPH Jessica R. Castle, MD Gregory J. Norman, PhD
Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Managed Care Cast Logo
February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS
On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
AJMC
April 2nd 2025

Prior Authorizations and the Adverse Impact on Continuity of Care

Jay S. Pickern, DBA
Prior authorizations create substantial administrative and financial burdens on physicians and patients and can disrupt the continuity of care.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Diabetes. | Image Credit: Minerva Studio - stock.adobe.com
March 28th 2025

Diabetes Risk Driven by Economic Disparity in Hispanic, Latino Communities

Cameron Santoro
Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.
FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo